Docetaxel and Radiotherapy for Lung Cancer
Author Information
Author(s): Koukourakis M I, Bahlitzanakis N, Froudarakis M, Giatromanolaki A, Georgoulias V, Koumiotaki S, Christodoulou M, Kyrias G, Skarlatos J, Kostantelos J, Beroukas K
Primary Institution: University Hospital of Heraklion, Crete, Greece
Hypothesis
Can weekly docetaxel combined with conventionally fractionated radiotherapy be better tolerated and equally effective in treating locally advanced non-small-cell lung carcinoma?
Conclusion
The combination of docetaxel and radiotherapy shows promise in treating locally advanced lung cancer, achieving a high complete response rate.
Supporting Evidence
- Docetaxel has shown remarkable radiosensitizing properties.
- A high response rate was observed in a previous study with concomitant boost radiotherapy and weekly docetaxel.
- Complete response was observed in 34% of patients.
- The overall survival rate at 1 year was 48%.
Takeaway
This study tested a new treatment for lung cancer using a drug called docetaxel with radiation, and it worked well for many patients.
Methodology
A phase II study evaluating the effects of weekly docetaxel and radiotherapy on patients with locally advanced NSCLC.
Limitations
The study had a small sample size and the results were not statistically significant.
Participant Demographics
Patients with T3, T4/N2, T3/M0-staged disease.
Statistical Information
P-Value
0.19
Statistical Significance
p=0.19
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website